1. Home
  2. MSN vs APM Comparison

MSN vs APM Comparison

Compare MSN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerson Radio Corporation

MSN

Emerson Radio Corporation

HOLD

Current Price

$0.49

Market Cap

8.4M

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

N/A

Current Price

$0.85

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MSN
APM
Founded
1948
2010
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
7.3M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
MSN
APM
Price
$0.49
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.9K
20.7K
Earning Date
02-17-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$77,829,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.65
52 Week High
$0.85
$4.47

Technical Indicators

Market Signals
Indicator
MSN
APM
Relative Strength Index (RSI) 67.88 48.11
Support Level $0.39 $0.75
Resistance Level $0.50 $0.89
Average True Range (ATR) 0.03 0.06
MACD 0.00 0.00
Stochastic Oscillator 93.72 44.11

Price Performance

Historical Comparison
MSN
APM

About MSN Emerson Radio Corporation

Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: